Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission
Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Advanced-Stage CKD Prevalence Rising Rapidly Worldwide: Multidimensional Modeling Study
The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention
AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.
Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study
LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.
Consider CGRP Inhibitors as a First-Line Option for Preventive Treatment of Migraine: New American Headache Society Consensus Statement
The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research
In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.
Elevated Albuminuria, Even Within Normoalbuminuric Range, May Be Linked to Elevated Risk for CKD Progression, Hepatic Failure
New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.
Risk for CHD Double Among Women who Binge Drink vs Men
ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.
Madrigal Announces US Availability of Resmetirom (Rezdiffra), First Patients Treated for NASH
Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.
Novel Web Tool Determines Consumer Eligibility for OTC Statin, With High Clinician Concordance
The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.
Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2
ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.
Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
Older, Mentally Altered Adults at Greatest Risk for Inappropriate Diagnosis of CAP
More than 1 in 10 older adults were misdiagnosed with community-acquired pneumonia and nearly all were treated with a full course of antibiotics, a new study found.
Nontraditional Risk Factors More Likely to Cause Stroke in Young Adults, Study Finds
Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.
ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray)
Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.
New Follow-Up Measure After Stool-Based CRC Test Could Improve Colonoscopy Rates, Outcomes
The quality performance measure is viable and reliable and could help improve early CRC detection rates via timely colonoscopy following abnormal stool-based test.
Atogepant Found More Effective for Migraine Prevention vs Rimegepant in New Analysis
Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.